Zacks Rating on Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 8 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.

Heron Therapeutics (HRTX) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $55 and the lowest price target forecast is $33. The average forecast of all the analysts is $43.75 and the expected standard deviation is $7.01.


Heron Therapeutics, Inc. has dropped 2.2% in the last five trading days, however, the shares have posted positive gains of 26.39% in the last 4 weeks. Heron Therapeutics, Inc. is up 1.7% in the last 3-month period. Year-to-Date the stock performance stands at -21.8%. Heron Therapeutics (NASDAQ:HRTX): On Tuesdays trading session , Opening price of the stock was $21.01 with an intraday high of $21.2355. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $20.71. However, the stock managed to close at $20.88, a loss of 0.62% for the day. On the previous day, the stock had closed at $21.01. The total traded volume of the day was 252,546 shares.

Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Companys product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Companys product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Companys other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.